Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page w- T' Q( i7 D3 W p
1 e* `2 v& ]+ m8 s/ p& }5 v7 ?8 d' n ^
( e G3 I" K) k: uSub-category:9 c$ n( X6 n# Y' k& C
Molecular Targets : V; q% W2 i: W- s# d
% D6 d7 P. T) e2 B( l4 d
1 _0 Y" r' g7 J
Category:
# Y6 B+ W0 L3 o0 g$ GTumor Biology : w9 |8 r' F1 Q5 w+ M
2 A) z I4 T: Q7 ?. |7 m' {
6 d+ d% Z, [* `- q8 |3 a6 dMeeting:$ R% k, o9 e( d, r( x6 B2 k
2011 ASCO Annual Meeting
. W1 P: A, i) h" h6 ~) x) X$ Q) s W5 R
' L$ |9 Y9 s G3 M7 {
Session Type and Session Title:
6 `! w/ ]9 ]7 M7 b4 @# vPoster Discussion Session, Tumor Biology
( S3 \, D/ c) f" O. m, z. H4 H, g' o
3 U$ a, o7 a- I# x3 m
9 k" i) {) a3 }Abstract No:
8 b% g. ~2 d- @+ I4 _' a8 E10517
1 H' s, k8 d' L& A g% c
4 @/ k9 E8 {- X5 T. v
8 K8 P# r+ R b7 [4 [ q- d' Z( FCitation:& r# |* X+ R* R, z6 f1 J- ~+ r
J Clin Oncol 29: 2011 (suppl; abstr 10517) ( R4 ^7 G) K, R" @
v9 ]! w2 o' W$ v0 Z$ T9 }& E4 T* N4 E$ ]* U
Author(s):+ f* }% h9 X% ~+ i! D- u0 f
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
3 q, l* c }' y- ^" S L2 \2 T
; {6 z& m0 Z% I! W: O7 F- ~* A, s/ r& c" O$ A2 [2 u& `: M4 w' U
) ?; U) ?' U/ V: F) D
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
7 x5 k+ }( i0 [
- i7 x: h" ]0 ?$ k( _, ]. dAbstract Disclosures
$ Z$ K* z: O [% S. Z8 E- v+ B
* ^; @% y" Z" W/ [5 sAbstract:
) x) ^7 r; C1 F ~; i# a1 _& f$ x6 {& W# C5 @% I) o7 G6 u* t5 {. M
% M6 j! @ e9 C+ l P9 b1 IBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
" Y) [% A! M/ o4 f4 H0 }
( }/ l: \4 l+ V5 F7 U7 }# R
7 p6 w* @9 a* [ @ |
- s3 |% E R. L! s: O
显身卡
